Ngā hua rapu - Amy N. Allen
- E whakaatu ana i te 1 - 3 hua o te 3
-
1
Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors mā Jiawan Wang, Kai Pollard, Amy N. Allen, Tushar Tomar, Dirk Pijnenburg, Zhan Yao, Fausto J. Rodríguez, Christine A. Pratilas
I whakaputaina 2020Artigo -
2
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma mā Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodríguez, John Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang, Christine A. Pratilas
I whakaputaina 2022Artigo -
3
A Secondary Mutation in<i>BRAF</i>Confers Resistance to RAF Inhibition in a<i>BRAF</i>V600E-Mutant Brain Tumor mā Jiawan Wang, Zhan Yao, Philip Jonsson, Amy N. Allen, Alice Can Ran Qin, Sharmeen Uddin, Ira J. Dunkel, Mary Petriccione, Katia Manova, Sofia Haque, Marc K. Rosenblum, David J. Pisapia, Neal Rosen, Barry S. Taylor, Christine A. Pratilas
I whakaputaina 2018Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Biology
Cancer research
Cell biology
Gene
Genetics
MAPK/ERK pathway
Medicine
Mutation
Biochemistry
Cancer
Dabrafenib
Effector
Enzyme
Farnesyltransferase
HRAS
In vivo
Internal medicine
KRAS
Kinase
Kinome
MEK inhibitor
Melanoma
Metastatic melanoma
Mutant
Neuroblastoma RAS viral oncogene homolog
Prenylation
Protein tyrosine phosphatase
Receptor
Receptor tyrosine kinase
Signal transduction